This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join us on 27 January 2025 to hear from Dr Michelle Oswal, Neurology Consultant, discussing 'Diagnosis to Treatment: Supporting the Primary Care Practitioner’s Migraine Management Journey' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
This meeting is available to join virtually. There will be local HCPs attending in-person and no travel or accommodation costs will be supported to attend this meeting.
Prescribing information can be found at the bottom of the page.
Join us on 27 January 2025 to hear from Dr Michelle Oswal, Neurology Consultant, discussing 'Diagnosis to Treatment: Supporting the Primary Care Practitioner’s Migraine Management Journey' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
This meeting is available to join virtually. There will be local HCPs attending in-person and no travel or accommodation costs will be supported to attend this meeting.
Dr Michelle Oswal is a consultant neurologist and the clinical lead for the headache service at Hillingdon Hospital in North West London.
Michelle qualified in medicine from University College London and trained in clinical neurology in Birmingham, Oxford and London. Michelle completed her PhD in Neurology at the Institute of Neurology, University College London and further post doctoral research at the University of Oxford. She received training and experience in complex headache at the National Hospital for Neurology and has subsequently led the development of a specialist headache service at Hillingdon hospital.
Since becoming a Consultant, she has worked on updating headache guidelines for NWL as well as local presentations to GPs to facilitate the management of primary headaches in the community. Michelle will also lead the neurology teaching programme for Imperial College medical students at Hillingdon.
Vydura®▼(rimegepant)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024